{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:54:32Z","timestamp":1781754872182,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01770-6","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:29:21Z","timestamp":1780457361000},"page":"3529-3554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data"],"prefix":"10.1007","volume":"16","author":[{"given":"Akio","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikiya","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-8808","authenticated-orcid":false,"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"11","key":"1770_CR1","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.14924\/dermatol.134.2741","volume":"134","author":"H Saeki","year":"2024","unstructured":"Saeki H, Ohya Y, Arakawa H, et\u00a0al. Clinical practice guidelines for the management of atopic dermatitis 2024. Jpn J Dermatol. 2024;134(11):2741\u2013843. https:\/\/doi.org\/10.14924\/dermatol.134.2741.","journal-title":"Jpn J Dermatol"},{"issue":"5","key":"1770_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2340\/00015555-0282","volume":"87","author":"S Reitamo","year":"2007","unstructured":"Reitamo S, Ortonne JP, Sand C, et\u00a0al. Long-term treatment with 0.1% tacrolimus ointment in adults with Atopic Dermatitis: results of a two-year, multicentre, non-comparative study. Acta Derm Venereol. 2007;87(5):406\u201312. https:\/\/doi.org\/10.2340\/00015555-0282.","journal-title":"Acta Derm Venereol"},{"issue":"6 Suppl","key":"1770_CR3","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1097\/DER.0000000000000841","volume":"33","author":"YA Leshem","year":"2022","unstructured":"Leshem YA, Sugerman PB, Weil C, et\u00a0al. Cutaneous comorbidities associated with atopic dermatitis in Israel: a retrospective real-world data analysis. Dermatitis. 2022;33(6 Suppl):S61\u20138. https:\/\/doi.org\/10.1097\/DER.0000000000000841.","journal-title":"Dermatitis"},{"issue":"2","key":"1770_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/der.0000000000000526","volume":"31","author":"Z Ren","year":"2020","unstructured":"Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. Dermatitis. 2020;31(2):157\u201364. https:\/\/doi.org\/10.1097\/der.0000000000000526.","journal-title":"Dermatitis"},{"issue":"5","key":"1770_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.clindermatol.2018.05.004","volume":"36","author":"J Fenner","year":"2018","unstructured":"Fenner J, Silverberg NB. Skin diseases associated with atopic dermatitis. Clin Dermatol. 2018;36(5):631\u201340. https:\/\/doi.org\/10.1016\/j.clindermatol.2018.05.004.","journal-title":"Clin Dermatol"},{"issue":"7","key":"1770_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1111\/bcp.15751","volume":"89","author":"S Zhao","year":"2023","unstructured":"Zhao S, Hwang A, Miller C, Lio P. Safety of topical medications in the management of paediatric atopic dermatitis: an updated systematic review. Br J Clin Pharmacol. 2023;89(7):2039\u201365. https:\/\/doi.org\/10.1111\/bcp.15751.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1770_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.123.001609","volume":"386","author":"H Hiyama","year":"2023","unstructured":"Hiyama H, Arichika N, Okada M, et\u00a0al. Pharmacological profile of difamilast, a novel selective phosphodiesterase 4 inhibitor, for topical treatment of atopic dermatitis. J Pharmacol Exp Ther. 2023;386(1):45\u201355. https:\/\/doi.org\/10.1124\/jpet.123.001609.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1770_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3820\/jjpe.27.11","volume":"27","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Overview of the DeSC database and utilization for clinical epidemiology and pharmacoepidemiology research. Jpn J Pharmacoepidemiol. 2022;27(1):11\u20138. https:\/\/doi.org\/10.3820\/jjpe.27.11.","journal-title":"Jpn J Pharmacoepidemiol"},{"issue":"3","key":"1770_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/pde.15223","volume":"40","author":"KE Rodriguez Baisi","year":"2023","unstructured":"Rodriguez Baisi KE, Weaver AL, Shakshouk H, Tollefson MM. Acne incidence in preadolescents and association with increased body mass index: a population-based retrospective cohort study of 643 cases with age- and sex-matched community controls. Pediatr Dermatol. 2023;40(3):428\u201333. https:\/\/doi.org\/10.1111\/pde.15223.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1770_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003452","volume":"9","author":"L Romani","year":"2015","unstructured":"Romani L, Koroivueta J, Steer AC, et\u00a0al. Scabies and impetigo prevalence and risk factors in Fiji: a national survey. PLoS Negl Trop Dis. 2015;9(3):e0003452. https:\/\/doi.org\/10.1371\/journal.pntd.0003452.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1770_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jaad.2019.04.009","volume":"81","author":"I Snast","year":"2019","unstructured":"Snast I, Dalal A, Twig G, et\u00a0al. Acne and obesity: a nationwide study of 600,404 adolescents. J Am Acad Dermatol. 2019;81(3):723\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.04.009.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1770_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000516232","volume":"238","author":"AHS Heng","year":"2022","unstructured":"Heng AHS, Say YH, Sio YY, Ng YT, Chew FT. Epidemiological risk factors associated with Acne Vulgaris presentation, severity, and scarring in a Singapore Chinese population: a cross-sectional study. Dermatology. 2022;238(2):226\u201335. https:\/\/doi.org\/10.1159\/000516232.","journal-title":"Dermatology"},{"issue":"7","key":"1770_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1398-9995.2010.02538.x","volume":"66","author":"T Hinz","year":"2011","unstructured":"Hinz T, Zaccaro D, Byron M, et\u00a0al. Atopic dermo-respiratory syndrome is a correlate of eczema herpeticum. Allergy. 2011;66(7):925\u201333. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02538.x.","journal-title":"Allergy"},{"issue":"4","key":"1770_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.diagmicrobio.2013.04.011","volume":"76","author":"M Durdu","year":"2013","unstructured":"Durdu M, G\u00fcran M, Ilkit M. Epidemiological characteristics of Malassezia folliculitis and use of the May-Gr\u00fcnwald-Giemsa stain to diagnose the infection. Diagn Microbiol Infect Dis. 2013;76(4):450\u20137. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2013.04.011.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"1770_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s13555-022-00751-9","volume":"12","author":"H Saeki","year":"2022","unstructured":"Saeki H, Imamura T, Yokota D, Tsubouchi H. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: a Phase III, long-term, open-label study. Dermatol Ther (Heidelb). 2022;12(7):1589\u2013601. https:\/\/doi.org\/10.1007\/s13555-022-00751-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1770_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/1346-8138.13408","volume":"43","author":"T Fukuie","year":"2016","unstructured":"Fukuie T, Hirakawa S, Narita M, et\u00a0al. Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study. J Dermatol. 2016;43(11):1283\u201392. https:\/\/doi.org\/10.1111\/1346-8138.13408.","journal-title":"J Dermatol"},{"issue":"2","key":"1770_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et\u00a0al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47(2):114\u201320. https:\/\/doi.org\/10.1111\/1346-8138.15173.","journal-title":"J Dermatol"},{"issue":"4","key":"1770_CR18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","volume":"85","author":"H Nakagawa","year":"2021","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et\u00a0al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85(4):854\u201362. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.014.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1770_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","volume":"126","author":"V Wang","year":"2021","unstructured":"Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3\u201312. https:\/\/doi.org\/10.1016\/j.anai.2020.08.002.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01770-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:24:24Z","timestamp":1781753064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01770-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Akio Tanaka has received consulting fees and\/or speaker honoraria from Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Torii Pharmaceutical Co., Ltd., Maruho Co., Ltd., Sanofi K.K., AbbVie GK, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Takeo Nakayama has no conflicts of interest related to this study. Outside of this work, Takeo Nakayama has received grants or contracts from I&H Co., Ltd., Cocokarafine Group Co., Ltd., Konica Minolta, Inc., NTT DATA, and Takeda Pharmaceutical Co. He has received consulting fees from Otsuka Pharmaceutical Co., Takeda Pharmaceutical Co., Johnson & Johnson K.K., and AstraZeneca plc. Furthermore, he has received payments or honoraria for lectures, manuscript writing, or educational events from Pfizer Japan Inc., MSD K.K., Chugai Pharmaceutical Co., Takeda Pharmaceutical Co., Janssen Pharmaceutical K.K., Boehringer Ingelheim International GmbH, Eli Lilly Japan K.K., Maruho Co., Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Allergan Japan K.K., Novo Nordisk Pharma Ltd., TOA EIYO Ltd., AbbVie Inc., Ono Pharmaceutical Co., Ltd., GSK plc, Alexion Pharmaceuticals, Inc., Canon Medical Systems Co., Kowa Company, Limited, Araya, Merck & Co., Amicus Therapeutics, Inc., CSL Behring, Amgen Inc., and Sanofi S.A. Additionally, Takeo Nakayama holds stock options in BonBon Inc. Miyuki Matsukawa, Rikiya Toda, Takahiro Tsuchiya, and Yasuhito Konishi are employees of Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved on July 17, 2024 by the Research Ethics Committee of Research and Development Division, Otsuka Pharmaceutical Co., Ltd. (approval no: 240702). As we used secondary anonymized data provided by the DeSC Healthcare and IQVIA, no individual-level informed consent was obtained. The questionnaire survey was conducted by the DeSC Healthcare in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in Japan and Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}